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A process is described to assess the commutability of a
reference material (RM) intended for use as a calibrator,
trueness control, or external quality assessment sample
based on the difference in bias between an RM and
clinical samples (CSs) measured using 2 different mea-
surement procedures (MPs). This difference in bias is
compared with a criterion based on a medically rele-
vant difference between an RM and CS results to make
a conclusion regarding commutability. When more
than 2MPs are included, the commutability is assessed
pairwise for all combinations of 2 MPs. This approach
allows the same criterion to be used for all combina-
tions of MPs included in the assessment. The assess-
ment is based on an error model that allows estimation
of various random and systematic sources of error,
including those from sample-specific effects of inter-
fering substances. An advantage of this approach is
that the difference in bias between an RM and the
average bias of CSs at the concentration (i.e., amount
of substance present or quantity value) of the RM is
determined and its uncertainty estimated. An RM is
considered fit for purpose for those MPs for which
commutability is demonstrated.
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Background
Commutability was defined in part 1 of this series (1 ).
This second part describes a statistical procedure to assess
commutability based on the difference in bias between a
reference material (RM)16 and clinical samples (CSs)
measured using 2 different measurement procedures
(MPs). This difference in bias is compared with a pre-
defined criterion to make a commutability judgment. If
more than 2 MPs are included in an assessment, the
commutability is assessed pairwise for all combinations of
2 MPs. If 1 of the MPs is a reference measurement pro-
cedure (RMP), then commutability of the RMwith each
of the MPs can be assessed vs the RMP, and pairwise
assessment among all MPs is not necessary.
As explained in part 1 of this series (1 ), anMP refers
to a written specification for how a measurement is per-
formed. A measuring system is a physical in vitro diag-
nostic (IVD) medical device manufactured according to
the MP specifications and used to make measurements
on CSs. Results for an RM and for CSs measured using
different measuring systems are used to assess commut-
ability of an RM. For simplicity, in this series of reports
we use the term MP when referring to either an MP or
results from a specific measuring system that is an IVD
medical device representative of the MP.
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Currently applied approaches for commutability as-
sessment use criteria based on the statistical distribution
of results for CSs observed between pairs of MPs. Linear
regression with prediction interval for the CSs has been
commonly used to determine whether an RM is com-
mutable (2, 3 ). When an RM belongs to the same pop-
ulation as the CSs, an observation of the RM has a spec-
ified probability (usually set to 95%) to fall within the
prediction interval limits. The prediction interval limits
are dependent on the random errors in each MP and can
be different for comparisons between different pairs of
MPs, which prevents using a single criterion based on the
intended use of the RM that is applicable to all MPs.
Using a prediction interval for assessment of commutability
is a test of the hypothesis that the RM can be considered to
belong to the same population as the CSs. Not rejecting a
hypothesis does not prove that it is true, and the prediction
interval approach does not quantify how closely the RM
agrees with the average relationship for the CSs at the con-
centration of interest. The uncertainty of the closeness of
agreement is neglected in the prediction interval approach.
An RMwith a bias exactly equal to the prediction limit has
a probability of approximately 50% to have a value within
the prediction limits. For these reasons, a different approach
is presented in this report.
An advantage of the approach described here is that
the difference in bias between an RM and the average bias
of CSs at the concentration of the RM is determined. This
approach allowsmore relevant assessment of commutability
being suitable for the intended use of an RMwith the same
criterionbeing used for all combinations ofMPs included in
the assessment. Another advantage is that the criterion to
make a commutability judgment can be based onmedically
relevant differences between RM and CS results, which is
not the case with the prediction interval approach.
In practice, an assessment of commutability cannot
include all possible performance conditions for an MP,
such as reagent lots, calibrator lots, and environmental
conditions. We must restrict the assessment to measure-
ments under specified conditions. In this report, the
specified conditions are 1 run with each of theMPs using
1 lot of reagents and calibrators, and each MP operated
and performing according to the specifications of its
manufacturer. The conclusions about commutability of
the RM are generalized to all future results using other
IVDmedical devices representative of the same MP with
the assumption that other IVD medical devices have
equivalent performance when operated under conditions
such as different reagent and calibrator lots, mainte-
nance, and operators. Limitations of this assumption
were discussed in part 1 of this series (1 ).
A worked example and explanation of the example
calculations are provided in the Commutability Example
Calculations and Commutability Example Explanation
sections of the Data Supplement that accompanies the
online version of this article at hiip://www.clinchem.
org/content/vol64/issue3.
Models, Experimental Designs, and
Assumptions
ASSESSMENT OF COMMUTABILITY
The experimental design considers the comparison of
results, x and y, obtained by 2 MPs. In a typical experi-
mental design, n CSs are measured in 1 run with each of
the MPs. A simple model for the difference between sin-
gle determinations of a CS is:
y  x  b  d  ey  ex, (1)
where:
 is the true concentration of the CS
b() is a common bias between the runs with the 2
MPs (the bias can be expressed by a continuous function
of  or a constant)
d is an error component specific for the CS (can be
considered as a random component in a population of
samples)
ex is a within-run component of variation for MP x
ey is a within-run component of variation for MP y.
The b() term is the part of the difference that can
be expressed by a continuous function of . Continuous
means that small changes in  result in small changes in
b(). The term d is a sample-specific difference. The SD
of component d is denoted d. The terms ey and ex are the
within-run components of variation with SDs e(x) and
e(y), in the following denoted x and y. Sample-specific
differences can be reduced only by an improved selectiv-
ity of 1 or both MPs.
Ideally, the variation within runs should be com-
pletely random, and the SDs x and y can be estimated
from repeated measurements. Under this ideal situation,
the SD of the sample-specific differences, d, can be es-
timated according to an approach suggested by Nilsson
(4 ). If the prerequisite of random variation is not satis-
fied, position effects within measurement runs must be
added to the model in Eq. 1. If the replicate measure-
ments of the CSs are adjacent, the d also includes the
SDs of the position effects. Miller et al. (5 ) suggested to
estimate the influence of possible position effects by per-
forming a second run with the CSs in a randomized order
in relation to the first run.
For commutability assessment, we recommend only
1 run and that the replicate measurements of the CSs are
adjacent, i.e., made one after the other, and that position
effects are investigated from measurements of the RMs
made in different positions. The terms b() and d will
usually depend on the specified population of CSs. The
SDs are assumed to be at least approximately indepen-
dent of the concentration. The distributions of the error
components are assumed to be approximately normal.
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COMMUTABILITY CRITERION
Commutability of the RM concerns how close the sys-
tematic difference (the bias) between the 2 MPs for the
RM is to the average bias for the CSs, b(), at the con-
centration of the RM.The difference between the bias for
the RM and the average bias for the CSs is denoted dRM
and expresses the closeness of agreement between the bias
for the RM and the bias for the CSs.
For assessment of commutability, we need to specify
a maximum value of dRM for the RM to be considered
commutable. This maximum value is called the commut-
ability criterion (C). For example,C can be themaximum
acceptable bias when one intends to use the RM as a
calibrator.
The SD of the contributions from the random com-
ponents e and d to the differences between the 2 MPs,
when the measured values are means of k replicates, is:
Random  d2  x2k  y2k (2)
Assuming a normal distribution, about 5% of the CS
differences will be larger than 2Random even if there is no
bias between the measurement procedures for the CSs.
For assessment of commutability vs C, we need an
estimate of dRM (for simplicity, we use the same symbol
for the estimate) and the expanded uncertainty U(dRM)
of the estimate. We will have 1 of the following 3
conditions:
1. The RM is commutable when the uncertainty interval
dRM  U(dRM) is within 0  C.
2. The RM is noncommutable when the uncertainty in-
terval dRM  U(dRM) is outside 0  C.
3. A commutability decision is inconclusive when the
uncertainty interval dRM  U(dRM) and 0  C are
overlapping.
WhenU(dRM) C, it will not be possible to verify com-
mutability. A too large U(dRM) can be caused by (a) an
unsuitable experimental design (too few replicates and/or
number of CSs) or (b) poor precision and/or poor selec-
tivity (large sample-specific differences). In the first case,
the experimental design should be reconsidered and the
experiment repeated with a new design. In the second
case, 1 or both MPs should be excluded from the com-
mutability assessment. The precision and selectivity of
each MP should be known in advance and considered in
the experimental design. As explained in part 1 of this
series (1 ), MPs should be prequalified for inclusion in a
commutability assessment, and MPs with inadequate
performance should be excluded. However, sample-
specific differences are estimated in this commutability
assessment experimental design and, when excessive, can
be a reason to exclude an MP from the data analysis and
to declare that the RM is not suitable for use with that
MP.
EXPERIMENTAL DESIGN
The experiment should be designed in such a way that it
is possible to obtain a reliable estimate of the value dRM
and the uncertainty of the estimate that is derived from
an estimate of the bias for the RM and for the CSs and
their uncertainties between 2 MPs. For identification of
the main sources contributing to the differences between
the MPs, it is also valuable to have estimates of the SDs
for replicates, position effects, and sample-specific differ-
ences. To obtain these estimates, the following experi-
mental design is recommended.
A number, n, of CSs are measured in k sequential
adjacent replicates in 1 run with bothMPs. The sequence
of measuring the CSs must be randomly assigned regard-
ing the concentrations (not in order of concentration) to
avoid the possibility of confounding between themeasur-
ing order and a trend in the bias. Each RM is measured in
p groups of k sequential adjacent replicates. The p groups
shall be spread out in the run, i.e., the groups represent
different positions in the series of measurements consti-
tuting a run. If there are known factors that may cause
systematic differences between measurements, these fac-
tors must be considered in the design and statistical anal-
ysis of the experiment. For example, if a multichannel
pipette is used for adding samples and/or reagents, it is
suitable to have an equal number of replicates from each
channel, i.e., k must at least be equal to the number of
channels.
The number of CSs, n, must be large enough and the
concentrations “evenly” distributed in the interval to
make it possible to distinguish between sample-specific
differences and a common bias between the MPs ex-
pressed by the continuous function b(). It is not neces-
sary for the CSs to cover the measuring interval of the
MPs, but it is important that the CSs cover a reasonable
concentration interval around each RM to allow a reli-
able estimate of bias between the MPs. An essential pre-
requisite for the statistical analysis is that the change in
the bias function between consecutive CS concentrations
is relatively small compared with the variation around
this function in a difference plot. Whether this prerequi-
site is satisfied can usually be judged from a visual inspec-
tion of the difference plot; see the Transformation of the
Data section. The n CSs should usually be at least 30 to
satisfy these requirements.
The minimum number of replicates, k, is 2, but
triplicate measurements are recommended to allow re-
moval of an outlier without removing all data for a CS or
an RM position. If precision of MPs is a major uncer-
tainty source, performing a larger number of replicates
might be necessary.
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Measuring the RMs in different positions makes it
possible to investigate position effects and better estimate
the uncertainty of the bias for an RM. The uncertainty of
the bias estimate depends on the SD of the position ef-
fects and the number of degrees of freedom must be
adequate for the estimate of this SD. We recommend
that the number of positions, p, should be at least 5.
The estimate of the commutability measure, dRM,
must be determined with acceptable uncertainty. As a
minimum requirement, we suggest that U(dRM) should
beC/2. The suggested minimum values of n, k, and p do
not guarantee that this requirement is satisfied, but the ex-
perimental designmakes it possible to identify the dominat-
ing contribution to the uncertainty and indicates where an
improvement of the experimental design is needed. An ex-
ample of an allocation ofmeasurementswith n 50, k 3,
p 5, and 5 RMs is given as an example in the Commut-
ability Example Calculations, worksheet Allocation, found
in the online Data Supplement.
TRANSFORMATION OF THE DATA
The statistical analysis uses difference plots with or with-
out transformation of the data for the statistical analysis.
Difference plots are preferred to regression because pos-
sible trends in bias or sample-specific effects over the
concentration interval are better identified.
For the statistical analysis, it is an advantage if the
SDs of the random components are independent of the
concentration. This requirement is often approximately
satisfied for either concentration or ln(concentration).
Other types of transformations can be used, but the ad-
vantage of using ln(concentration) is that it is easy to
interpret the results. If SDs and differences of ln(concen-
tration) are multiplied by 100, we obtain approximate
values of CVs and relative differences in percent for con-
centration. The decision whether to use concentration or
ln(concentration) for the statistical analysis is based on
the experimental results. A precision profile as shown in
Fig. 1 can be constructed for each MP by calculating the
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Fig. 1. Precision proﬁles as SD vs concentration.
(A) shows an approximately constant SD over the concentration interval. (B) shows a proportional relationship between SD and concentration.
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SD and the mean of the replicates for each CS and plot-
ting the SDs against the means. If a precision profile does
not indicate a strong (more than a factor 2) dependence
between the SD and the concentrations, as in Fig. 1A, the
SDs are pooled to a common estimate for each MP, de-
noted sx and sy, respectively. If the SDs seem to be pro-
portional to the concentrations, as in Fig. 1B, it is an
indication that ln(concentration) should be used; how-
ever, the next paragraph must also be considered.
Difference plots are examined for yi  xi and
ln(yi)  ln(xi) on the y axis against xi, when MP x is an
RMP, or when neither of the MPs is an RMP, (yi	 xi)/2
on the x axis. The width of the scatter is caused by the
combined influence of the SDs of all random compo-
nents. From a visual inspection of the 2 difference plots,
one identifies the plot where the scatter width has the
smallest dependence on the concentration to determine
whether concentration or ln(concentration) should
be used for the statistical analysis. Fig. 2 shows difference
plots for yi  xi and ln(yi)  ln(xi) against the mean
concentration. It is obvious in this case that ln(concen-
tration) is preferred because of the consistent scatter over
the concentration interval. It is more important that the
width of the scatter is independent of the concentration
for a difference plot than for the precision profiles in the
previous paragraph. If the scatter width is independent of
the concentration but precision profiles are not indepen-
dent of the concentration, the contributions from the SD
within triplicates, x and y, should be negligible. If nei-
ther concentration nor ln(concentration) gives an ap-
proximately constant scatter width, the statistical analysis
should be performed for different concentration inter-
vals, within which the scatter width is approximately con-
stant. When transformation to ln(concentration) is used,
the statistical analyses are performed with the ln(concen-
tration) values. In precision profiles and difference plots,
it is appropriate to have concentration on the x axis (pos-
sibly with a logarithmic scale) and use the ln(concentra-
tion) values on the y axis.
The decisions whether to transform and whether to
perform the statistical analysis for different concentration
intervals are based on subjective judgments. Models and
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Fig. 2. Difference in concentration (A) and ln(concentration) (B) for the same data vs mean concentration of both MPs.
(A) is from spreadsheet tab CSTrans found in the online Data Supplement. (B) is from spreadsheet tab CSTrans (2) found in the online
Data Supplement.
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assumptions are always approximations of reality, and it
is better to use a subjective judgment than to use a fixed
model with no judgment at all.
HANDLING OF OUTLIERS
Outliers are observations that are distant from the main
part of the observations. An outlier may be because of
occasional problems in an MP, experimental mistakes,
mix-up of results, transcription errors, or other types of
operator errors. If such a cause is identified, the observa-
tion should be corrected or excluded. There may, how-
ever, be outliers for which the causes cannot be identified;
for instance, when some of the CSs in a comparison of
MPs have properties that cause2 separate distributions
of the differences between the MPs. To determine how
close the bias for the RM is to the average bias for the CSs
is not meaningful if the average bias represents 2 popula-
tions of CSs. The populations of CSs corresponding to
these different distributions should, if possible, be iden-
tified (e.g., healthy and diseased donors) and commut-
ability assessments performed for each population. If the
outliers are relatively few (10%), the only reasonable
approach often is to exclude them. If the outlier results
are not excluded, the calculation of the mean and the SD
may be misleading.
Often a visual inspection is sufficient for identifica-
tion of possible outliers. Obvious outliers can often be
identified from, for instance, precision profiles and dif-
ference plots. If there are borderline cases, one can per-
form the analysis both without and with exclusions. If
inclusion or exclusion of potential outliers gives essen-
tially the same estimates, the observations can be
included.
COMPONENTS OF VARIATION WITHIN RUNS ESTIMATED
FROM THE RM
For each RM, we have p positions with k replicates in
each position. First, the mean and SD for each position
are calculated. The SD of the position means is denoted
sPos-mean, and the pooled SD of the SDs within positions is
denoted se. When the number of replicates is the same in
each position, the pooled variance is the mean of the
variances in the different positions. The pooled SD is the
square root of the pooled variance. If there are no posi-
tion effects, both
k  sPos-mean and se should be estimates
ofe (the SDwithin positions), and to test the hypothesis
of no position effects, the test statistic is:
F 
ksPos-mean
2
se
2 (3)
The SD of the position effects is estimated by:
sPos  sPos-mean2  se2k (4)
When the value under the root sign is negative, (F  1)
sPos is set to 0. When 1 RM is included, pooled esti-
mates can be calculated as the square root of the mean
variances. When calculating the pooled SD of the posi-
tion effects, a negative value of the variance under the
root sign in Eq. 4 shall not be replaced by 0.
ESTIMATE DIFFERENCES BETWEEN MPs FROM THE CSs
The analysis is performed for either concentration or ln-
(concentration). In the following, xi and yi denote either
the mean of concentration or ln(concentration) for sam-
ple i. From the replicates of each CS, an estimate of SD
between replicates is obtained. A pooled estimate of the
SD between replicates is obtained from all CSs by calcu-
lating the square root of the mean of the variances for the
individual CSs. The pooled SDs between replicates are
denoted sx and sy, respectively. If the SDs between repli-
cates for the RM(s) do not differ significantly (F-test)
from the pooled estimates for the CSs, then the SDs for
the RM(s) can be included in sx and sy. Otherwise, sepa-
rate estimates are used for the RM(s) and the CSs.
The differences Bi  yi  xi are plotted against the
mean concentrations of the 2 MPs or against xi, when x
represents an RMP. A difference plot can be character-
ized by 2 components: a continuous function fitted to the
center of the scatter and the variation around the func-
tion, expressed by the SD. The first component is an
estimate of b(). The SD of the scatter should be
Random, defined in Eq. 2.
It is often reasonable to assume that the maximum
difference between consecutive concentrations of the CSs
corresponds to a maximum change of the bias function,
which is small compared with the contribution from the
within-run variation to the observed differences Bi. Con-
secutive B values should then have approximately the
same expected mean, and we can estimate the SD around
the bias function from each pair of consecutive values.
Pooling the estimates from all the consecutive differences
gives the SD estimate based on the mean square succes-
sive difference (MSSD).
sMSSD   12n  1 
i  1
n  1
Bi  1  Bi
2, (5)
where Bi is ordered according to ascending values of xi or
(xi	 yi)/2. sMSSD is used as an estimate of Random, which
includes the variability associated with sample-specific
differences and does not include the variability associated
with a trend in differences. This estimate should be of the
same size as the usual estimate of the SD of the B values,
calculated as:
sB   1n  1  
i  1
n
Bi  BCS
2, (6)
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when the difference between the measurement proce-
dures is a constant (i.e., no trend). BCS is the mean of the
differences Bi. Thus, when sMSSD is significantly smaller
than sB, a trend is indicated. For n 20, the distribution
of (sMSSD/sB)
2 is approximately normal with mean 1 and
SD   1n 11 1n 1; seeHald (6 ). This test sup-
ports the decision regardless of whether the bias function
is constant in a concentration interval.
When there are sample-specific effects, the sMSSD is
an estimate of the SD of the contributions from the ran-
dom components e and d to the differences between the 2
MPs according to Eq. 2. When there are no sample-
specific differences, sMSSD should be an estimate of:
Random0  x2  y2k (7)
and the hypothesis of no sample-specific differences can
be tested by:
F 
k  sMSSD
2
sx
2  sy
2 (8)
where F has an F distribution.
With the suggested experimental design (triplicate
measurements), k is equal to 3. The appropriate numbers
of degrees of freedom in the numerator and the denom-
inator are not obvious. sMSSD is estimated from n  1
differences, but they are not independent and the degrees
of freedommust be less than n 1. If sMSSD is calculated
from the differences between B2  B1, B4  B3, and so
on, it is based on n/2 independent differences when n is
even and (n 1)/2 when n is odd. Thus, the number of
degrees of freedom for the estimate sMSSD should at least
be equal to the integer part of n/2, and this value is used
in the test.
In the denominator in Eq. 8, we have the sum of 2
variance estimates, and theWelch–Satterthwaite formula
can be used to calculate the effective number of degrees of
freedom (7 ). In this application, the minimum number
of the degrees of freedom for sx and sy is used. By using
minimum numbers of degrees of freedom both in the
numerator and the denominator, the F-test should be
conservative (i.e., the probability of incorrectly rejecting
the hypothesis of no sample-specific differences is less
than the nominal significance level).
An estimate of d, the SD of the sample-specific
differences, is obtained by:
sd  sMSSD2  sx2  sy2k . (9)
If the expression under the root sign is negative, the esti-
mate sd  0 is used.
When there are no trends, sB may be used instead of
sMSSD in Eq. 9.
If there are position effects, these effects are included
in the estimate sd. By using the estimates of position
effects for RMs, we can correct for these effects and ob-
tain a corrected value [denoted sd(corr)]
sdcorr  sMSSD2  sx2  sy2k  sPos x2  sPos y2 .
(10)
The commutability assessment and the calculation of the
expanded uncertaintyU(dRM) are performed in the same
way regardless of whether there are significant sample-
specific differences. However, if the uncertainty is too large
for a conclusive decision and the commutability assessment
must be repeated, it is essential to identify the error compo-
nent that gives the dominating contribution to the uncer-
tainty. In other words, shall we increase the number of rep-
licates or the number of CS or should we adjust the
qualifications to include CS or exclude an MP from com-
mutability assessment because of nonselectivity for themea-
surand. One of the advantages with this approach is that no
assumption of a specific model for b() is required for the
estimation of the sample-specific differences. We can sepa-
rate sample-specific differences from a common bias as-
sumed to be a continuous function of the concentration.
COMMUTABILITY OF THE RM
The commutability of the RM is assessed as the difference
between the bias for the RM and the average bias for the
CSs, b(), between 2 MPs at the concentration of the
RM. This difference is denoted dRM. To obtain an esti-
mate of dRM, we need an estimate of the bias for the RM
and b() for the CSs. The bias for the RM is estimated by
the observed difference BRM yRM xRM, and the stan-
dard uncertainty is estimated by
uBRM  sPos-mean x2  sPos-mean y2p . (11)
sPos-mean(x) and sPos-mean(y) are the SDs between position
means for the RMs defined in the Components of Vari-
ation Within Runs Estimated from the RMs section.
The appropriate estimate of b() at the concentra-
tion of the RM depends on the outcome of the experi-
ment. The following outcomes are possible (note that the
uncertainty of BRM is the same):
A: The bias function b() is approximately constant
in the whole concentration interval, and the CSs
bracket the concentration of the RM
b() is estimated by BCS and the standard uncertainty by:
uBCS 
sB
n. (12)
dRM is estimated by BRM  BCS with the standard
uncertainty:
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udRM  sPos-mean x2  sPos-mean y2p  sB2n (13)
B: The bias function b() is approximately constant
in a concentration interval enclosing the RM
It is possible to find a concentration interval with q CSs
bracketing the RM where b() seems to be approxi-
mately constant. In this case, q must be large enough to
give an acceptable uncertainty. We have the same situa-
tion as in A but with q CSs instead of n; thus, we have:
udRM  sPos-mean x2  sPos-mean y2p  sB2q (14)
C: The bias function b() has an approximately linear
trend in an interval where there are q/2 CSs on
each side of the RM
The number q is even and must be large enough to give
an acceptable uncertainty. The CSs should also be
“evenly” distributed in the concentration interval.
The mean bias of the q CSs bracketing the RM is
used as an approximate estimate of b() at the concen-
tration of the RM, but if the uncertainty is calculated
according to Eq. 12, it will be an overestimation, as the
trend in b() contributes to sB. Instead of sB, it is more
reasonable to use sMSSD according to Eq. 5, and the un-
certainty is given by:
udRM  sPos-mean x2  sPos-mean y2p  sMSSD2q
(15)
A large magnitude in the bias trend indicates a severe
problem, and the commutability assessment may not be
possible.
D: The prerequisites for situations A, B, and C are not
satisfied (e.g., we have none or only a few CSs
with concentrations close to that of the RM)
It may be tempting to fit a model to b() and extrapolate
or interpolate to the concentration interval of interest.
Forcing the data into a model is not acceptable. With no
or fewCSs in the relevant concentration interval, we have
no possibilities to verify that the model is reasonable.
DETERMINING THE COVERAGE FACTOR FOR THE
UNCERTAINTY ESTIMATE
To evaluate commutability, we need the expanded un-
certainty U(dRM) obtained by multiplying u(dRM) by a
suitable coverage factor. If we want a risk of 5% to erro-
neously classify an RM just outsideC as commutable, the
coverage of the expanded uncertainty shall be 90%. An
uncertainty interval dRMU(dRM) within 0 C should
be equivalent to rejecting the hypothesis that dRM  C
at the 5% level of significance. The standard uncertain-
ties in Eqs. 13, 14, and 15 are a combination of 3 com-
ponents, which makes the calculation of the coverage
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Fig. 3. Difference in bias between RMs (red squares) and CSs (black diamonds) vsmean concentration of the 2measuring systems.
The solid black line is themean bias between the 2measurement procedures for the CSs. The red dashed lines are the commutability criteria.
The red squares are themean bias between the 2MPs for the RMs, and the bars are the uncertainty in the difference in bias between RM and
CS mean bias. RM1, RM2, and RM4 are indeterminate; RM3 is commutable; RM5 is noncommutable. Fig. 3 is from the spreadsheet tab
CS&RMDiff found in the online Data Supplement.
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factor complicated. However, with p  4 (pooled esti-
mates of sPos-mean from at least 2 RMs) and n (or q) 12,
a coverage factor of 1.9 gives a coverage of at least 90%.
This coverage factor is suggested when there are no rea-
sons for a larger value. With an infinite number of de-
grees of freedom, the coverage factor is about 1.7. The
sizes of n, q, and p discussed in this section concern the
minimum values, which can justify a coverage factor of
1.9. The numbers recommended in the experimental de-
sign section meet these minimum sizes.
Presentation of Commutability Assessment
A suitable way to illustrate the results from a commut-
ability assessment is shown in Fig. 3 based on the
example data provided in the online Data Supplement.
The mean bias between the 2MPs for the CSs is shown
as a solid line (black). The dashed lines (red) are the
commutability criteria. The squares (red) are the mean
bias between the 2 MPs for the RMs, and the bars
represent the uncertainty in the difference in bias be-
tween RM and CS mean biases. RM1, RM2, and RM4
are indeterminate; RM3 is commutable; RM5 is
noncommutable.
Commutability Assessment for More Than Two
Measurement Procedures
In most cases, more than 2 MPs are included in a com-
mutability assessment, and all combinations of 2MPs are
evaluated as pairs as described here and shown in Fig. 3
for 1 pair. The commutability of an RM determined for
all combinations of MPs examined can be presented in
different ways. One convenient summary representation
for all combinations of pairs of MPs is shown in Fig. 4A.
In this example, the RM is not commutable forMP8 and
is commutable for the other MPs in the assessment. In
cases when an RMP is available for a measurand, all clin-
ical laboratory MPs can be compared with the RMP (see
Fig. 4B), and it is not necessary to compare all combina-
tions of MP pairs with each other. Considerations for the
fraction of MPs for which an RM should be commutable
to be suitable for its intended use were discussed in part 1
of this series.
Conclusion
The approach to commutability assessment described
here gives estimates of the differences in bias between
RMs and CSs when 2MPs are compared. The uncertain-
ties of these estimates are also calculated. A single fixed
criterion for commutability of an RM can be applied to
all combinations of pairs of MPs. The criterion can be
selected based on the intended use of an RM as a calibra-
tor, trueness control, or external quality assessment ma-
terial, and the criterion can be related to the requirements
for medical decisions based on the laboratory test results.
The commutability assessment determines whether the
difference in bias plus its uncertainty fulfills the criterion
for a conclusion that an RM is commutable, noncom-
mutable, or indeterminate for pairs of MPs. Conclusions
regarding suitability for use of an RM can be made by
assessing its commutability for all MPs in the assessment
as described in part 1 of this series (1 ).
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